What the Study Found (In Plain English)
Published in Atherosclerosis (2008), this randomized controlled trial evaluating 21 human participants investigated: This study assessed the efficacy of rosuvastatin for reducing plasma low-density lipoprotein (LDL) cholesterol after 18 weeks of open-label, forced titration in patients with homozygous familial hypercholesterolaemia (hoFH) and compared the efficacy of rosuvastatin 80 mg and atorvastatin 80 mg. Key clinical takeaway: All treatments were well tolerated. Rosuvastatin may have therapeutic value in the management of hoFH.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Atherosclerosis, 2008-03-15; N = 21; Rigor 88/100): All treatments were well tolerated. Rosuvastatin may have therapeutic value in the management of hoFH.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.